[en] Gestational trophoblastic neoplasia (GTN) is extremely rare, but has a very good prognosis, with a cure rate close to 100%, for low-risk diseases. This article describes the case of a healthy 28-year-old nulliparous patient with GTN resistant to multiple lines of treatment. The era of immunotherapy is revolutionizing oncology, having already proved its worth in the treatment of many cancers. This article will have a specific focus on the emerging role of immunotherapy in the treatment of GTN. Unfortunately, the use of an immune checkpoint inhibitor (ICI) failed in our case, emphasizing on the necessity to clearly define the future role of immune therapy in GTN. Finally, given the rapid progression of the disease after hysterectomy, induction with Paclitaxel- Ifosfamide and then intensification with high-dose Carboplatin and Etoposide with peripheral blood stem cell support was given as a rescue therapy with still curative intent.
Disciplines :
Oncology Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Enuset, Anne; Department of Gynecology and Obstetrics, Université Catholique de Louvain, Brussels, Belgium
Duck, Lionel; Onco-Hematology and Palliative Care, Clinique Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium
Petre, Claudia; Department of Gynecology and Obstetrics, Clinique Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium
Machiels, Jean-Pascal; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC, Pole MIRO), Université Catholique de Louvain, Brussels, Belgium
Goffin, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques
Language :
English
Title :
Case report: Multidrug resistant gestational trophoblastic neoplasia: focus on failure of immunotherapy and success of high-dose chemotherapy.
Ngan H Seckl M Berkowitz R Xiang Y Golfier F Sekharan P et al. Diagnostis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. (2021) 155:86–93. doi: 10.1002/ijgo.13877
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. (2010) 203:531–9. doi: 10.1016/j.ajog.2010.06.073
Joyce CM Fitzgerald B McCarthy TV Coulter J O’Donoghue K. Advances in the diagnosis and early management of gestational trophoblastic disease. BJM Med. (2022) 1:e000321. doi: 10.1136/bmjmed-2022–000321
Clark J Slater S Seckl M. Treatment of gestational trophoblastic disease in the 2020s. Curr Opin Obstet Gynecol. (2021) 33:7–12. doi: 10.1097/GCO.0000000000000674
Albright BB Shorter JM Mastroyannis SA Ko EM Schreiber CA Sonalkar S. Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin normalization following molar pregnancy: a systematic review and meta-analysis. Obstet Gynecol. (2020) 135:12–23. doi: 10.1097/AOG.0000000000003566
Ngan HY Bender H Benedet JL Jones H Montruccoli GC Pecorelli S et al. Gestational Trophoblastic Neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. (2003) 83:175–7. doi: 10.1016/s0020–7292(03)90120–2
Weng Y Liu Y Benjoed C Wu X Tang S Li X et al. Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis. J Zheijang Univ Sci B. (2022) 23:218–29. doi: 10.1631/jzus.B2100895
Winter MC. Treatment of low-risk gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol. (2021) 74:67–80. doi: 10.1016/j.bpobgyn.2021.01.006
Mendes da Silva AL do Nascimento Monteiro K Yazaki Sun S Urban Berbely A. Gestational trophoblastic neoplasia: Novelties and challenges. Placenta. (2021) 116:38–42. doi: 10.1016/j.placenta.2021.02.013
You B Pollet-Villard M Fronton L Labrousse C Schott A-M Hajri T et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. (2010) 21:1643–50. doi: 10.1093/annonc/mdq033
Prouvot C Golfier F Massardier J You B Lotz J-P Patrier S et al. Efficacy and safety of second-line 5-day Dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia. Int J Gynecol Cancer. (2018) 28:1038–44. doi: 10.1097/IGC.0000000000001248
Abbott M Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. (2019) 35:150923. doi: 10.1016/j.soncn.2019.08.002
Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Science. (2013) 342:1432–3. doi: 10.1126/science.342.6165.1432
Mangili G Sabetta G Cioffi R Rabaiotti E Candotti G Pella F et al. Current evidence on immunotherapy for gestational trophoblastic neoplasia (GTN). Cancers. (2022) 14:2782. doi: 10.3390/cancers14112782
Fisher RA Maher GJ. Genetics of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. (2021) 74:29–41. doi: 10.1016/j.bpobgyn.2021.01.004
Veras E Jurman RJ Wan T-L Shih l-M. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. (2017) 36:146–53. doi: 10.1097/PGP.0000000000000305
Bolze P-A Patrier S Massardier J Hajri T Abbas F Schott AM et al. PD-L1 expression in premalignant and Malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. (2017) 27:554–61. doi: 10.1097/IGC.0000000000000892
Lu B Teng X Fu G Bao L Tang J Shi H et al. Analysis of PD-L1 expression in trophoblastic tissues and tumors. Hum Pathol. (2019) 84:202–12. doi: 10.1016/j.humpath.2018.10.001
Chen S Li T Meng L Liu K. Advances in immunotherapy and molecular targeted therapy of gestational trophoblastic tumor: current practice and future perspectives. Am J Cancer Res. (2022) 12:2422–32.
Deleuze A Massard C Le Du F You B Lefeuvre-Plesse C Bolze P-A et al. Management of trophoblastic tumors: review of evidence, current practice, and future directions. Expert Rev Anticancer Ther. (2023) 23:699–708. doi: 10.1080/14737140.2023.2215438
Salman L Bouchard-Fortier G Covens A. Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options Oncol. (2022) 23:1035–43. doi: 10.1007/s11864–022-00988–8
Wang X Cang W Liu X Cheng Y Wan X Feng F et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study. EClinicalMedicine. (2023) 59:101974. doi: 10.1016/j.eclinm.2023.101974
Baas IO Westermann AM You B Bolze P-A Seckl M Ghorani E. Immunotherapy for GTN: a new paradigm. Gynecol Obstet Invest. (2023). doi: 10.1159/000533972
Hennah L Seckl M Ghorani E. Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy. Int J Gynecol Cancer. (2023) 33:414–9. doi: 10.1136/ijgc-2022–003771
Braga A Balthar E Souza LCS Samora M Rech M Madi JM et al. Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia – systematic review with a presentation of the first 4 Brazilian cases. Clinics (Sao Paulo). (2023) 78:100260. doi: 10.1016/j.clinsp.2023.100260
Ghorani E Kaur B Fisher RA Short D Joneborg U Carlson JW et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. (2017) 390:2343–5. doi: 10.1016/S0140–6736(17)32894–5
Choi MC Oh J Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer. (2019) 121:94–7. doi: 10.1016/j.ejca.2019.08.024
Wang T Guo W Ren X Lang F Ma Y Qiu C et al. Progress of immunotherapies in gestational trophoblastic neoplasms. J Cancer Res Clin Oncol. (2023) 149:15275–85. doi: 10.1007/s00432–023-05010–8
Lehmann M Hosa H Bartl T Tsibulak I Polterauer S Pötsch N et al. Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report. Gynecol Oncol Rep. (2023) 49:101259. doi: 10.1016/j.gore.2023.101259
Cheng H Zong L Kong Y Wang X Gu Y Cang W et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. (2021) 22:1609–17. doi: 10.1016/S1470–2045(21)00460–5
You B Bolze P-A Lotz J-P Massardier J Gladieff L Joly F et al. Avelumab in Patient with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN Phase II Trial. J Clin Oncol. (2020) 38:3129–37. doi: 10.1200/JCO.20.00803
Huang M Pinto A Castillo RS Slomovitz BM. Complete Serologic Response to Pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. (2017) 35(27):3172–4. doi: 10.1200/JCO.2017.74.4052
Bolze P-A You B Lotz J-P Massardier J Gladieff L Joly F et al. Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy. Ann Oncol. (2020) 31:823–5. doi: 10.1016/j.annonc.2020.02.015
Alazzam M Tidy J Osborne R Coleman R Hancock BW Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. (2016), CD008891. doi: 10.1002/14651858.CD008891.pub3
Jareemit N Therasakvichya S Freitas F Paiva G Ramìrez LA Berkowitz RS et al. EMACO for treatment of gestational trophoblastic neoplasia: a multinational multicenter study. Gynecol Oncol. (2023) 170:114–22. doi: 10.1016/j.ygyno.2022.12.020
Braga A Elias KM Horowitz NS Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol. (2021) 74:81–96. doi: 10.1016/j.bpobgyn.2021.01.005
Turan T Karacay O Tulunay G Boran N Koc S Bozok S et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. (2006) 16:1432–8. doi: 10.1136/ijgc-00009577-200605000-00074
Couder F Golfier F Vaudoyer F Massardier J Guastalla J-P Hajri T et al. Naissance vivante après hystérectomie partielle pour choriocarcinome gestationnel chimiorésistant. Gynecol Obstet Fertil. (2012) 40:376–8. doi: 10.1016/j.gyobfe.2012.02.006
Case AM Wilson S Colgan TJ Greenblatt EM. Fertility-sparing surgery, with subsequent pregnancy, in persistent gestational trophoblastic neoplasia. Hum Reprod. (2001) 16:360–4. doi: 10.1093/humrep/16.2.360
Frijstein MM Lok CAR Short D Singh K Fisher RA Hancock BW et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer. (2019) 109:162–71. doi: 10.1016/j.ejca.2018.12.033
El-Helw LM Seckl MJ Haynes R Evans LS Lorigan PC Long J et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer. (2005) 93:620–1. doi: 10.1038/sj.bjc.6602771
Benigno BB. High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease. Int J Gynecol Cancer. (2013) 23:1331–3. doi: 10.1097/IGC.0b013e3182a017fc
Yamamoto E Niimi K Fujikake K Nishida T Murata M Mitsuma A et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review. Mol Clin Oncol. (2016) 5:660–4. doi: 10.3892/mco.2016.1011
